Subgroup | Â | n | Recurrence (n [%]) | DFS (P) |
---|---|---|---|---|
Chemotherapy (n = 61) | ||||
   c-myc | Amplified | 19 | 3 (15.8) | 0.1748 |
 | Nonamplified | 42 | 2 (4.8) |  |
HER-2/neu | Amplified | 26 | 1 (3.8) | 0.2552 |
 | Nonamplified | 35 | 4 (11.4) |  |
Endocrine therapy (n= 99) | ||||
   c-myc | Amplified | 15 | 1 (6.7) | 0.3325 |
 | Nonamplified | 84 | 2 (2.4) |  |
HER-2/neu | Amplified | 22 | 1 (4.5) | 0.6641 |
 | Nonamplified | 77 | 2 (2.6) |  |
No therapy (n = 21) | ||||
   c-myc | Amplified | 5 | 1 (20.0) | 0.0209* |
 | Nonamplified | 16 | 0 (0) |  |
HER-2/neu | Amplified | 7 | 0 (0) | 0.4969 |
 | Nonamplified | 14 | 1 (7.1) |  |